Myeloperoxidase (MPO) concentrations predict adverse clinical outcomes in setting acute coronary syndromes (ACS) and heart failure, but the prognostic role of MPO in SCAD with atherosclerotic burden is poorly understood [9]. Here, MPO is linked to acute coronary syndrome.